Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: Importance of fallopian tube dysplasia

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 183-188

  Leunen, K ^a   Legius, E ^a   Moerman, P ^a   Amant, F ^a   Neven, P ^a   Vergote, I ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

BRCA; Fallopian tube dysplasia; Prophylactic salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; EPITHELIUM DYSPLASIA; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC PROCEDURES; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYSTERECTOMY; LAPAROSCOPIC SURGERY; LAPAROTOMY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CANCER; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; UNIVERSITY HOSPITAL; UTERINE TUBE DISEASE; UTERINE TUBE DYSPLASIA;

ADULT; AGE FACTORS; BIOPSY, NEEDLE; BREAST NEOPLASMS; COHORT STUDIES; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PEDIGREE; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 33645339791     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00287.x     Document Type: Article

References (41)

1. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002 346 1660 2.
2. Klaren HM van't Veer LJ van Leeuwen FE Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003 95 941 7.
3. Antoniou A Pharoah PDP Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003 72 1117 30.
4. Gayther SA Russell P Harrington P Antoniou AC Easton DF Ponder BAJ. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer susceptibility genes. Am J Hum Genet 1999 65 1021 9.
5. Thompson D Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001 68 410 9.
6. Rish HA McLaughlin JR Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001 68 700 10.
7. King MC Marks JH Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003 302 643 6.
8. Claes K Poppe B Coene I Paepe AD Messiaen L. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 2004 90 1244 351.
9. Hall JM Lee MK Newman B et al. Linkage of early-onset breast cancer to chromosome 17q21. Science 1990 250 1684 9.
10. Wooster R Neuhausen SL Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994 265 2088 90.
11. Schwartz MD Kaufman E Peshkin BN et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003 21 4034 41.
12. Rebbeck TR Lynch HT Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002 346 1616 22.
13. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2002 38S S15 7.
14. Kauff ND Satagopan JM Robson ME et al. Risk-reducing salpingo- oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002 346 1609 15.
15. Rutter JL Wacholder S Chetrit A et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003 95 1072 8.
16. Laframboise S Nedelcu R Murphy J Cole DE Rosen B. Use of CA 125 and ultrasound in high-risk women. Int J Gynecol Cancer 2002 12 86 91.
17. Haites N Gregory H. Overview of the clinical benefits of breast cancer. In Morrison PJ Hodgson SV Haites NE eds. Familial breast and ovarian cancer: genetics, screening and management. Cambridge Cambridge University Press 2002 6 21.
18. Rose PG Shrigley R Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 2000 77 317 20.
19. Aziz S Kuperstein G Rosen B. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001 80 341 5.
20. Agoff SN Mendelin JE Grieco VS Garcia RL. Unexpected gynecologic neoplasms in patient with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology and clinical follow-up care. Am J Surg Pathol 2002 26 171 8.
21. Levine DA Argenta PA Yee CJ et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003 21 4222 7.
22. Brose MS Rebbeck TR Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002 94 1365 72.
23. Paley PJ Swisher EM Garcia RL et al. Occult cancer of the fallopian tube in BRCA1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001 80 176 80.
24. Colgan TJ Murphy J Cole DE Narod S Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001 25 1283 9.
25. Piver MS Jishi MF Tsukada Y Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993 71 2751 5.
26. Alvarado-Cabrero I Young RH Vamvaka EC Sculy RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999 72 367 79.
27. Lavie O Hornreich G Ben Arie A Renbaum P Levy-Lahad E Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 2000 96 28 32.
28. Levine DA Lin O Barakat RR et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001 80 395 8.
29. Lavie O Hornreich G Ben-Arie A et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004 92 521 4.
30. Piek JM van Diest PJ Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001 195 451 6.
31. Markman M Zaino RJ Fleming PA Barakat RR. Carcinoma of the fallopian tube. In Hoskins WJ Perez CA Young RC eds. Principles and practice of gynaecologic oncology. Philadelphia, PA Lippincott Williams & Wilkins 2000 1104 15.
32. Tung KH Goodman MT Wu AH et al. Aggregation of ovarian cancer with breast, ovarian colorectal and prostate cancer in first-degree relatives. Am J Epidemiol 2004 159 750 8.
33. Colgan TJ Boerner SL Murphu J et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002 85 397 403.
34. Olopade OI Arioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 2004 10 S5 9.
35. Taylor M. Psychological consequences of surgical menopause. J Reprod Med 2001 46 Suppl. 24 317 24.
36. Modugno F and the ovarian cancer and high risk women symposium presenters. Ovarian cancer and high-risk women - implications for prevention, screening, and early detection. Gynecol Oncol 2003 91 15 31.
37. Cabaret AS Leveque J Dugast C Blanchot J Graal JY. Problems raised by the gynaecologic management of women with BRCA1 & 2 mutations. Gynecol Obstet Fertil 2003 31 370 7.
38. Rebbeck TR Levin AM Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA 1 mutation carriers 1999. J Natl Cancer Inst 1999 91 1475 9.
39. Valerie Beral and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 362 419 27.
40. Rosen B Kwon J Fung Kee Fung M et al. Systematic review of management options for woman with a hereditary predisposition to ovarian cancer. Gynecol Oncol 2004 93 280 6.
41. Carcangiu ML Radice P Manoukian S et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004 23 35 40.